sm-8668 has been researched along with Dermatomycoses* in 2 studies
1 trial(s) available for sm-8668 and Dermatomycoses
Article | Year |
---|---|
Treatment of coccidioidomycosis with SCH 39304.
A new oral triazole antifungal, SCH 39304, was administered to 54 patients with progressive infections due to Coccidioides immitis from six collaborating centers. Patients were grouped according to site of infection including chronic pulmonary (25), bone/joint (17) and skin/soft tissue (12). The median age was 40 years; 83% were male, 52% white, 13% HIV-infected and 35% had failed previous therapy. The majority of patients were treated with either 100 mg or 200 mg day-1. One patient on renal dialysis received 300 mg day-1. Baseline abnormalities were reassessed for evidence of efficacy every 4 months and expressed in a standardized scoring system. Cumulative overall response rates at 4, 8 and 12 months were 7%, 36% and 66% respectively. Twelve month response rates by disease were 77% (pulmonary), 62% (skin/soft tissue) and 31% (bone/joint). Fifteen patients failed therapy although seven of these were still on treatment when the study was discontinued. Two failed due to toxicity. Possible symptoms or signs of toxicity occurred in 24 (44%) patients and were generally mild. SCH 39304 is an effective and well tolerated therapy for progressive forms of coccidioidomycosis. Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antifungal Agents; Coccidioidomycosis; Dermatomycoses; Drug Administration Schedule; Female; HIV Infections; Humans; Joint Diseases; Lung Diseases, Fungal; Male; Middle Aged; Treatment Outcome; Triazoles | 1994 |
1 other study(ies) available for sm-8668 and Dermatomycoses
Article | Year |
---|---|
In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304.
SCH 39304, a new triazole antifungal agent, is a 50:50 racemic mixture of two enantiomers, SCH 42427 and SCH 42426. The activities of these three compounds were compared in a series of in vitro and in vivo experiments. SCH 42427 was twofold more active in vitro against a variety of yeasts and dermatophytes than SCH 39304, while SCH 42426 was inactive (MICs greater than 64 micrograms/ml). In a systemic Candida albicans infection in mice, SCH 42427 administered orally (p.o.) (50% protective dose [PD50], 0.17 mg/kg of body weight; 50% effective dose, [ED50], 0.47 mg/kg) had greater efficacy than SCH 39304 (PD50, 0.21 mg/kg; ED50, 0.62 mg/kg) and SCH 42426 (greater than 100 mg/kg for PD50 and ED50). In a pulmonary Aspergillus flavus infection in mice, SCH 42427 p.o. (PD50, 13 mg/kg) was also more effective than SCH 39304 (18 mg/kg) and SCH 42426 (greater than 250 mg/kg). In a C. albicans vaginal infection in hamsters, SCH 42427 p.o. (ED50, 3.5 mg/kg) was more active than SCH 39304 (8.5 mg/kg) and SCH 42426 (320 mg/kg). Following topical administration, against a Trichophyton mentagrophytes infection in guinea pigs, SCH 42427 was about 2-fold more active than SCH 39304 and about 100-fold more active than SCH 42426. These and other results indicated that SCH 42427 is the active enantiomer, responsible for all the antifungal activity observed with SCH 39304. Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Candidiasis; Candidiasis, Vulvovaginal; Cricetinae; Dermatomycoses; Female; Fungi; Guinea Pigs; Male; Mesocricetus; Mice; Microbial Sensitivity Tests; Rats; Rats, Inbred Strains; Stereoisomerism; Triazoles; Trichophyton | 1992 |